Large Abdominal Hernia Repair With SurgiMend 3.0



What is the purpose of this trial?

The rate of hernia recurrence at one year following repair of a large abdominal hernia with a biologic mesh is high, ranging from 30% to 100%, with a reported historic average rate of 40%. The purpose of this study is to evaluate the rate of hernia recurrence at one year following repair with SurgiMend 3.0, an FDA-cleared novel biologic mesh, the hypothesis being that such rate will be less than 20% at one year, representing a 50% reduction over the historic rate of 40%.

Participation Guidelines

19 Years and older

Click here for detailed information about who can participate in this trial.

Boston Medical Center
Cook County Hospital
Massachusetts General Hospital
Oregon Health and Science University
State University of New York - Upstate Medical University
TEI Biosciences Inc.
University of Southern California
Yale University
July 2010
Last Updated:
September 27, 2013
Study HIC#:
1005006844 ID: NCT00892333